BACKGROUND Celecoxib has been used to treat hip discomfort and functional difficulties associated with osteonecrosis of the femoral head(ONFH),although significant adverse reactions often follow long-term use.Extracor...BACKGROUND Celecoxib has been used to treat hip discomfort and functional difficulties associated with osteonecrosis of the femoral head(ONFH),although significant adverse reactions often follow long-term use.Extracorporeal shock wave therapy(ESWT)can delay the progression of ONFH,alleviate the pain and functional limitations it causes,and avoid the adverse effects of celecoxib.AIM To investigate the effects of individual ESWT,a treatment alternative to the use of celecoxib,in alleviating pain and dysfunction caused by ONFH.METHODS This was a randomized,controlled,double-blinded,non-inferiority trial.We examined 80 patients for eligibility in this study;8 patients were excluded based on inclusion and exclusion criteria.A total of 72 subjects with ONFH were randomly assigned to group A(n=36;celecoxib+alendronate+sham-placebo shock wave)or group B(n=36;individual focused shock wave[ESWT based on magnetic resonance imaging three-dimensional(MRI-3D)reconstruction]+alendronate).The outcomes were assessed at baseline,at the end of treatment,and at an 8-wk follow-up.The primary outcome measure was treatment efficiency after 2 wk of intervention using the Harris hip score(HHS)(improvement of 10 points or more from the baseline was deemed sufficient).Secondary outcome measures were post-treatment HHS,visual analog scale(VAS),and Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC)scores.RESULTS After treatment,the pain treatment efficiency of group B was greater than that of group A(69%vs 51%;95%CI:4.56%to 40.56%),with non-inferiority thresholds of-4.56%and-10%,respectively.Furthermore,the HHS,WOMAC,and VAS scores in group B dramatically improved during the follow-up period as compared to those in group A(P<0.001).After therapy,the VAS and WOMAC in group A were significantly improved from the 2nd to 8th wk(P<0.001),although HHS was only significantly altered at the 2 wk point(P<0.001).On the 1st d and 2nd wk after treatment,HHS and VAS scores were different between groups,with the difference in HHS lasting until week 4.Neither group had severe complications such as skin ulcer infection or lower limb motorsensory disturbance.CONCLUSION Individual shock wave therapy(ESWT)based on MRI-3D reconstruction was not inferior to celecoxib in managing hip pain and restrictions associated with ONFH.展开更多
股骨头坏死(osteonecrosis of the femoral head,ONFH)是骨科常见难治性、致残性疾病,是引起髋关节疼痛及功能障碍的常见原因之一,给患者个人、家庭和社会造成了沉重的负担。体外冲击波疗法(extracorporeal shock wave ther-apy,ESWT)...股骨头坏死(osteonecrosis of the femoral head,ONFH)是骨科常见难治性、致残性疾病,是引起髋关节疼痛及功能障碍的常见原因之一,给患者个人、家庭和社会造成了沉重的负担。体外冲击波疗法(extracorporeal shock wave ther-apy,ESWT)具有非侵入、安全、有效的特点,已被广泛应用于包括股骨头坏死在内的骨肌疾病临床治疗领域。然而,现阶段ONFH的ESWT方案在适应证选择、治疗参数、评价方法等层面缺乏统一共识,限制了疗法的推广及应用。因此,如何规范、科学、有效地为早、中期ONFH患者提供ESWT干预是临床医生关注的问题。本指南由中国人民解放军总医院第三医学中心、中日友好医院牵头,组织中国研究型医院学会冲击波医学专业委员会,以及国内ONFH、ESWT领域专家,参考国内外最新文献、结合国内临床经验及实际情况,采用改良2011年版牛津大学循证医学中心(Oxford Center for Evidence-Based Medicine,OCEBM)证据级别及推荐等级标准,遵循2014年版《世界卫生组织指南制订手册》及中华医学会发布的《中国制订/修订临床诊疗指南的指导原则(2022版)》。同时参考了指南研究与评价工具Ⅱ(Appraisal of Guide-lines for Research and EvaluationⅡ,AGREEⅡ)、卫生保健实践指南的报告条目(Reporting Items for Practice Guidelines in Healthcare,RIGHT)以及中国临床实践指南评价体系(Appraisal of Guidelines for Research and Evaluation in China,A-GREE-China)等方法,遴选出医生最为关注的9个临床问题,并最终形成9条循证医学推荐意见。本指南旨在为ONFH ESWT治疗技术的推广应用提供建设性意见及依据,提高ESWT的科学性和规范性。展开更多
目的:探究C形臂X线定位下多次小直径钻孔联合体外冲击波疗法(extracorporeal shock wave therapy,ESWT)对早期股骨头坏死(osteonecrosis of the femoral head,ONFH)的临床疗效。方法:回顾分析2015年5月至2017年5月收治的早期ONFH患者106...目的:探究C形臂X线定位下多次小直径钻孔联合体外冲击波疗法(extracorporeal shock wave therapy,ESWT)对早期股骨头坏死(osteonecrosis of the femoral head,ONFH)的临床疗效。方法:回顾分析2015年5月至2017年5月收治的早期ONFH患者106例,其中53例采用C形臂X线定位下多次小直径钻孔联合ESWT治疗作为观察组,男41例,女12例,年龄22~70(45.85±6.01)岁;另外53例仅采用ESWT治疗作为对照组,男34例,女19例,年龄20~68(45.12±5.83)岁。观察比较两组患者治疗前后髋关节屈曲范围、外展内收活动范围、ONFH面积比例,比较两组治疗前后改良Harris评分(modified Harris hip scores,mHHS),视觉模拟评分(visual analog scale,VAS)。采用Kaplan-Meier法绘制生存曲线,比较两组患者治疗后3年随访期间的股骨头生存率。结果:患者均无创口愈合不良及感染等并发症的发生。106例患者均获得随访,时间28~36(31.06±4.28)个月。观察组mHHS总分、髋关节屈曲范围、髋关节外展内收活动范围由治疗前(63.85±5.42)分、(23.79±2.21)°、(32.40±4.19)°分别增加至治疗后2年的(85.51±5.69)分、(34.65±2.73)°、(43.32±5.71)°(P<0.05);对照组分别由治疗前的(64.73±5.64)分、(23.82±2.18)°、(32.45±4.13)°增加至治疗后2年的(81.65±5.48)分、(32.79±2.87)°、(39.75±5.68)°(P<0.05)。观察组VAS、ONFH面积比例分别由治疗前的(5.76±1.41)分、(35.07±4.96)%降低至治疗后2年的(3.39±1.02)分、(22.04±3.23)%(P<0.05),对照组分别由治疗前的(5.73±1.45)分、(35.24±5.18)%降低至治疗后2年的(4.43±1.21)分、(28.32±3.76)%(P<0.05);治疗后两组间各项指标比较,差异均有统计学意义(P<0.05)。观察组患者治疗后3年的股骨头生存率明显高于对照组(P<0.05)。结论:C形臂X线定位下多次小直径钻孔联合ESWT治疗早期ONFH能够明显改善患者的临床症状,缓解疼痛,提高临床疗效。展开更多
股骨头坏死(osteonecrosis of the femoral head,ONFH)作为骨科领域的一种多发难治性疾病,尚无可逆性的治疗技术去改变其坏死状态。现阶段,在疾病发展的晚期多采用髋关节置换术(totalhiparthroplasty,THA),被公认为是最有效的治疗方法,...股骨头坏死(osteonecrosis of the femoral head,ONFH)作为骨科领域的一种多发难治性疾病,尚无可逆性的治疗技术去改变其坏死状态。现阶段,在疾病发展的晚期多采用髋关节置换术(totalhiparthroplasty,THA),被公认为是最有效的治疗方法,但此方法具有假体寿命有限、费用昂贵、患者及社会经济负担严重等弊端。故如何在股骨头坏死的早中期进行干预治疗以保留自体髋关节,一直是学者们孜孜不倦所追求的目标。基于国内外文献资料,本文将就股骨头坏死保髋治疗的新进展进行综述,以期为股骨头坏死的治疗研究提供灵感思路,进一步促进保髋医疗技术的发展。展开更多
文摘BACKGROUND Celecoxib has been used to treat hip discomfort and functional difficulties associated with osteonecrosis of the femoral head(ONFH),although significant adverse reactions often follow long-term use.Extracorporeal shock wave therapy(ESWT)can delay the progression of ONFH,alleviate the pain and functional limitations it causes,and avoid the adverse effects of celecoxib.AIM To investigate the effects of individual ESWT,a treatment alternative to the use of celecoxib,in alleviating pain and dysfunction caused by ONFH.METHODS This was a randomized,controlled,double-blinded,non-inferiority trial.We examined 80 patients for eligibility in this study;8 patients were excluded based on inclusion and exclusion criteria.A total of 72 subjects with ONFH were randomly assigned to group A(n=36;celecoxib+alendronate+sham-placebo shock wave)or group B(n=36;individual focused shock wave[ESWT based on magnetic resonance imaging three-dimensional(MRI-3D)reconstruction]+alendronate).The outcomes were assessed at baseline,at the end of treatment,and at an 8-wk follow-up.The primary outcome measure was treatment efficiency after 2 wk of intervention using the Harris hip score(HHS)(improvement of 10 points or more from the baseline was deemed sufficient).Secondary outcome measures were post-treatment HHS,visual analog scale(VAS),and Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC)scores.RESULTS After treatment,the pain treatment efficiency of group B was greater than that of group A(69%vs 51%;95%CI:4.56%to 40.56%),with non-inferiority thresholds of-4.56%and-10%,respectively.Furthermore,the HHS,WOMAC,and VAS scores in group B dramatically improved during the follow-up period as compared to those in group A(P<0.001).After therapy,the VAS and WOMAC in group A were significantly improved from the 2nd to 8th wk(P<0.001),although HHS was only significantly altered at the 2 wk point(P<0.001).On the 1st d and 2nd wk after treatment,HHS and VAS scores were different between groups,with the difference in HHS lasting until week 4.Neither group had severe complications such as skin ulcer infection or lower limb motorsensory disturbance.CONCLUSION Individual shock wave therapy(ESWT)based on MRI-3D reconstruction was not inferior to celecoxib in managing hip pain and restrictions associated with ONFH.
文摘股骨头坏死(osteonecrosis of the femoral head,ONFH)是骨科常见难治性、致残性疾病,是引起髋关节疼痛及功能障碍的常见原因之一,给患者个人、家庭和社会造成了沉重的负担。体外冲击波疗法(extracorporeal shock wave ther-apy,ESWT)具有非侵入、安全、有效的特点,已被广泛应用于包括股骨头坏死在内的骨肌疾病临床治疗领域。然而,现阶段ONFH的ESWT方案在适应证选择、治疗参数、评价方法等层面缺乏统一共识,限制了疗法的推广及应用。因此,如何规范、科学、有效地为早、中期ONFH患者提供ESWT干预是临床医生关注的问题。本指南由中国人民解放军总医院第三医学中心、中日友好医院牵头,组织中国研究型医院学会冲击波医学专业委员会,以及国内ONFH、ESWT领域专家,参考国内外最新文献、结合国内临床经验及实际情况,采用改良2011年版牛津大学循证医学中心(Oxford Center for Evidence-Based Medicine,OCEBM)证据级别及推荐等级标准,遵循2014年版《世界卫生组织指南制订手册》及中华医学会发布的《中国制订/修订临床诊疗指南的指导原则(2022版)》。同时参考了指南研究与评价工具Ⅱ(Appraisal of Guide-lines for Research and EvaluationⅡ,AGREEⅡ)、卫生保健实践指南的报告条目(Reporting Items for Practice Guidelines in Healthcare,RIGHT)以及中国临床实践指南评价体系(Appraisal of Guidelines for Research and Evaluation in China,A-GREE-China)等方法,遴选出医生最为关注的9个临床问题,并最终形成9条循证医学推荐意见。本指南旨在为ONFH ESWT治疗技术的推广应用提供建设性意见及依据,提高ESWT的科学性和规范性。
文摘目的:探究C形臂X线定位下多次小直径钻孔联合体外冲击波疗法(extracorporeal shock wave therapy,ESWT)对早期股骨头坏死(osteonecrosis of the femoral head,ONFH)的临床疗效。方法:回顾分析2015年5月至2017年5月收治的早期ONFH患者106例,其中53例采用C形臂X线定位下多次小直径钻孔联合ESWT治疗作为观察组,男41例,女12例,年龄22~70(45.85±6.01)岁;另外53例仅采用ESWT治疗作为对照组,男34例,女19例,年龄20~68(45.12±5.83)岁。观察比较两组患者治疗前后髋关节屈曲范围、外展内收活动范围、ONFH面积比例,比较两组治疗前后改良Harris评分(modified Harris hip scores,mHHS),视觉模拟评分(visual analog scale,VAS)。采用Kaplan-Meier法绘制生存曲线,比较两组患者治疗后3年随访期间的股骨头生存率。结果:患者均无创口愈合不良及感染等并发症的发生。106例患者均获得随访,时间28~36(31.06±4.28)个月。观察组mHHS总分、髋关节屈曲范围、髋关节外展内收活动范围由治疗前(63.85±5.42)分、(23.79±2.21)°、(32.40±4.19)°分别增加至治疗后2年的(85.51±5.69)分、(34.65±2.73)°、(43.32±5.71)°(P<0.05);对照组分别由治疗前的(64.73±5.64)分、(23.82±2.18)°、(32.45±4.13)°增加至治疗后2年的(81.65±5.48)分、(32.79±2.87)°、(39.75±5.68)°(P<0.05)。观察组VAS、ONFH面积比例分别由治疗前的(5.76±1.41)分、(35.07±4.96)%降低至治疗后2年的(3.39±1.02)分、(22.04±3.23)%(P<0.05),对照组分别由治疗前的(5.73±1.45)分、(35.24±5.18)%降低至治疗后2年的(4.43±1.21)分、(28.32±3.76)%(P<0.05);治疗后两组间各项指标比较,差异均有统计学意义(P<0.05)。观察组患者治疗后3年的股骨头生存率明显高于对照组(P<0.05)。结论:C形臂X线定位下多次小直径钻孔联合ESWT治疗早期ONFH能够明显改善患者的临床症状,缓解疼痛,提高临床疗效。
文摘股骨头坏死(osteonecrosis of the femoral head,ONFH)作为骨科领域的一种多发难治性疾病,尚无可逆性的治疗技术去改变其坏死状态。现阶段,在疾病发展的晚期多采用髋关节置换术(totalhiparthroplasty,THA),被公认为是最有效的治疗方法,但此方法具有假体寿命有限、费用昂贵、患者及社会经济负担严重等弊端。故如何在股骨头坏死的早中期进行干预治疗以保留自体髋关节,一直是学者们孜孜不倦所追求的目标。基于国内外文献资料,本文将就股骨头坏死保髋治疗的新进展进行综述,以期为股骨头坏死的治疗研究提供灵感思路,进一步促进保髋医疗技术的发展。
